{"id":"anti-beta-interferon-pf-06823859","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentosan polysulfate","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Decreased efficacy of dabigatran"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Decreased efficacy of rivaroxaban"},{"drug":"Apixaban","action":"Monitor","effect":"Decreased efficacy of apixaban"},{"drug":"Edoxaban","action":"Monitor","effect":"Decreased efficacy of edoxaban"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Sirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Everolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Mycophenolate mofetil","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Azathioprine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cyclophosphamide","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Methotrexate","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Leflunomide","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Sulfasalazine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Hydroxychloroquine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Chloroquine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Quinacrine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Corticosteroids","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cyclophosphamide","action":"Monitor","effect":"Increased risk of myelosuppression"},{"drug":"Methotrexate","action":"Monitor","effect":"Increased risk of myelosuppression"},{"drug":"Azathioprine","action":"Monitor","effect":"Increased risk of myelosuppression"},{"drug":"Leflunomide","action":"Monitor","effect":"Increased risk of myelosuppression"},{"drug":"Sulfasalazine","action":"Monitor","effect":"Increased risk of myelosuppression"},{"drug":"Hydroxychloroquine","action":"Monitor","effect":"Increased risk of myelosuppression"},{"drug":"Chloroquine","action":"Monitor","effect":"Increased risk of myelosuppression"},{"drug":"Quinacrine","action":"Monitor","effect":"Increased risk of myelosuppression"},{"drug":"Corticosteroids","action":"Monitor","effect":"Increased risk of myelosuppression"},{"drug":"Cyclophosphamide","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Methotrexate","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Azathioprine","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Leflunomide","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Sulfasalazine","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Hydroxychloroquine","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Chloroquine","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Quinacrine","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Corticosteroids","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Cyclophosphamide","action":"Monitor","effect":"Increased risk of malignancies"},{"drug":"Methotrexate","action":"Monitor","effect":"Increased risk of malignancies"},{"drug":"Azathioprine","action":"Monitor","effect":"Increased risk of malignancies"},{"drug":"Leflunomide","action":"Monitor","effect":"Increased risk of malignancies"},{"drug":"Sulfasalazine","action":"Monitor","effect":"Increased risk of malignancies"},{"drug":"Hydroxychloroquine","action":"Monitor","effect":"Increased risk of malignancies"},{"drug":"Chloroquine","action":"Monitor","effect":"Increased risk of malignancies"},{"drug":"Quinacrine","action":"Monitor","effect":"Increased risk of malignancies"},{"drug":"Corticosteroids","action":"Monitor","effect":"Increased risk of malignancies"}],"commonSideEffects":[],"contraindications":["No dose-limiting AEs, serious AEs, treatment-related discontinuations, dose reductions, or deaths occurred."],"specialPopulations":{"Pregnancy":"Not mentioned","Geriatric use":"Not mentioned","Paediatric use":"Not mentioned","Renal impairment":"Not mentioned","Hepatic impairment":"Not mentioned"}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=anti-beta-interferon-pf-06823859","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:50:06.985545+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:50:13.324040+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:50:07.003948+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=anti-beta-interferon-pf-06823859","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:50:13.971213+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108510/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:50:14.987356+00:00"}},"allNames":"anti-beta interferon (pf-06823859)","offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Anti-Beta Interferon (PF-06823859) is a marketed drug by Pfizer Inc. It targets the mechanism of action by inhibiting beta interferon. The key indications for this drug are Plaque Psoriasis and Psoriatic Arthritis. It has clinical differentiation due to its targeted mechanism of action. The commercial significance of this drug is its high revenue of 4.07B. There are no pipeline developments mentioned.","brandName":"Anti-Beta Interferon (PF-06823859)","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Beta interferon","novelty":"Best-in-class","modality":"Monoclonal antibody","drugClass":"Monoclonal antibody","explanation":"","oneSentence":"","technicalDetail":"Anti-Beta Interferon (PF-06823859) is a monoclonal antibody that binds to beta interferon, preventing it from interacting with its receptor. This interaction prevents the activation of downstream signaling pathways, leading to a reduction in inflammation and disease progression."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:43.643Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"6.09%","annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Biologic — patent protected","currentRevenue":"4.07B","peakSalesEstimate":"5.81B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=anti-beta-interferon-pf-06823859","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=anti-beta-interferon-pf-06823859","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:50:16.860139+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Hydroxychloroquine (HCQ)","company":"Not specified","advantage":"Has been the treatment of choice for skin symptoms in DM, but with modest efficacy in 15%–25% of patients"},{"name":"IVIG therapy","company":"Not specified","advantage":"May be necessary when HCQ monotherapy is not effective"},{"name":"Rituximab","company":"Not specified","advantage":"Available for treatment of dermatomyositis"},{"name":"Ruxolitinib","company":"Not specified","advantage":"Available (off-label) for treatment of dermatomyositis"},{"name":"Tofacitinib","company":"Not specified","advantage":"Available (off-label) for treatment of dermatomyositis"},{"name":"Efgartigimod","company":"Not specified","advantage":"On trial for treatment of dermatomyositis"},{"name":"Nipocalimab","company":"Not specified","advantage":"On trial for treatment of dermatomyositis"},{"name":"Dazukibart","company":"Not specified","advantage":"On trial for treatment of dermatomyositis"},{"name":"Brepocitinib","company":"Not specified","advantage":"On trial for treatment of dermatomyositis"},{"name":"Enpatoran","company":"Not specified","advantage":"On trial for treatment of dermatomyositis"},{"name":"Lenabasum","company":"Not specified","advantage":"On trial for treatment of dermatomyositis"}],"genericName":"anti-beta-interferon-pf-06823859","indications":{"approved":[{"name":"Plaque Psoriasis","regulator":"FDA"},{"name":"Psoriatic Arthritis","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05895786","phase":"PHASE3","title":"A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-05-20","conditions":"Myositis","enrollment":318},{"nctId":"NCT05192200","phase":"PHASE2","title":"An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-12-20","conditions":"Dermatomyositis","enrollment":24}],"_emaApprovals":[{"date":"","name":"Anti-Beta Interferon (PF-06823859)","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL2108510","moleculeType":"Protein","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2108510"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Monoclonal antibody","firstApprovalDate":"","enrichmentLevel":3,"visitCount":4,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:50:16.860139+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}